ANDA 216076, held by Teva Pharms. Midostaurin.
As of Nov 14, 2026, ANDA 216076 (Midostaurin), held by Teva Pharms, was first approved by FDA on Apr 29, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2024 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Midostaurin25MG ยท capsule;oral | Midostaurin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
